Table 4.
Summary for sources and responsible bioactive molecules of exosomes that induce inflammasome activation
Sources of exosomes | Releasing cell type | Target cell(s)/tissue(s) | Effector molecule(s) | Reference |
---|---|---|---|---|
With paracrine effects | ||||
Amniotic fluid and malignant ascites | N/A | Macrophage | N/A | 57 |
IL-1β-treated osteoarthritic chondrocytes | Cartilage cell | Macrophage | miR-449a-5p | 107 |
Lipopolysaccharide (LPS)-treated Raw264.7 macrophages | Immune cell | Hepatocyte | N/A | 75 |
Palmitate-treated HepG2 cells# | Liver cancer cell | Macrophage | N/A | 108 |
Plasma of HIV-infected patients | HIV-target cell (Immune cell) | Non-HIV infected macrophage | HIV protein Nef | 105 |
Plasma of traumatic brain injury patients# | N/A | Pulmonary endothelial cells | Apoptosis associated speck-like protein containing a caspase recruitment domain (ASC) | 78 |
With paracrine and/or autocrine effects | ||||
Blue-light irradiated human adult retinal pigment epithelial (hARPE-19) cells | Epithelial cell | Non-irradiated retinal pigment epithelial cell | Active forms of IL-1β, IL-18, and caspase-1 | 9 |
LPS/nigericin-treated bone marrow-derived macrophages (BMDMs) | Immune cell | Naive or nigericin-treated BMDMs | N/A | 106 |
Manganese/LPS-treated microglial cells | Immune cell | Naive microglial cell | Apoptosis associated speck-like protein containing a caspase recruitment domain (ASC) | 71 |
#EVs were used in the study.
N/A: No available information.